Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.
Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine.
Karagianis
Jamie
J
Clinical Research, Eli Lilly Canada Inc., Toronto, Ontario, Canada. karagianis_jamie@lilly.com
Hoffmann
Vicki Poole
VP
Arranz
Belen
B
Treuer
Tamás
T
Maguire
Gerald A
GA
de Haan
Lieuwe
L
Chawla
Bharat
B
D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D000077152:Olanzapine; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy; D012995:Solubility; D013607:Tablets; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D013607:Tablets; D001569:Benzodiazepines; D000077152:Olanzapine